Emedastine Difumarate Sustained-release Capsules

Function and indications:
Emedastine fumarate eye drops: This product is suitable for temporary relief of the signs and symptoms of allergic conjunctivitis. Emedastine fumarate sustained-release capsules: This product is used for allergic rhinitis and urticaria.
Usage and dosage:
Emedastine fumarate eye drops: The recommended dose is 1 drop per affected eye, 2 times a day, which can be increased to 4 times a day if necessary. Emedastine fumarate sustained-release capsules: The usual dose for adults is 2 times a day, 1-2 mg each time, orally after breakfast and before bedtime.
Adverse reactions:
Emedastine fumarate eye drops: 13 clinical trials collected 696 patients, and EMADINE was administered to both eyes 1-4 times a day for 42 days. In clinical trials, nearly 7% of patients were expected to experience adverse reactions after using EMADINE; however, less than 1% of patients discontinued treatment due to adverse reactions. No serious ocular or systemic adverse reactions were reported in clinical trials. The most common adverse reaction was eye pain, which accounted for 2.0% of the total adverse reactions. The following are adverse reactions observed in clinical trials or obtained from post-marketing experience. They are classified according to system organs and graded according to the following rules: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000), very rare (<1/10000) and unknown (cannot be assessed based on known data). Within each frequency group, adverse reactions are listed in descending order of severity. Heart disease unknown: tachycardia Nervous system diseases Common: headache Uncommon: sinus headache, taste disturbance Eye diseases Common: eye pain, eye irritation, blurred vision, itchy eyes, dry eyes, corneal staining, conjunctival congestion Uncommon: corneal infiltration, foreign body sensation in the eye, increased tearing, visual fatigue, eye congestion Skin and subcutaneous tissue diseases Uncommon: rash Psychiatric diseases Uncommon: different dreams Emedastine Fumarate Sustained Release Capsules: Foreign experience shows that about 7.34% of patients experience adverse reactions after taking Emedastine Fumarate Sustained Release Preparations. Mainly including drowsiness (63%), fatigue (0.61%), thirst (0.23%), abdominal pain (0.14%), staggering (0.13%), headache, heaviness of the head, dizziness (0.1%), etc. In addition, rare (incidence rate less than 0.1%) chest tightness, palpitations, itching, rash, nausea, vomiting, loss of appetite, upper abdominal discomfort, abdominal pain, diarrhea, constipation, tinnitus, abnormal skin sensation, abnormal liver function, thrombocytopenia, abnormal urine test (urine protein, urine occult blood, hematuria), increased blood pressure, etc. In addition, foreign data seem to show that the incidence of adverse reactions in women is slightly higher than that in men.
Contraindications:
Emedastine fumarate eye drops: contraindicated for those who are allergic to emedastine fumarate and any ingredients in this product. Emedastine fumarate sustained-release capsules: safety for children has not yet been established. Because this product inhibits intradermal reactions to allergens such as penicillin